Treatment of Bullous Skin Infection (Likely MRSA)
For a bullous skin infection suspected to be MRSA, empiric antibiotic therapy targeting MRSA should be initiated immediately, with the specific regimen determined by severity: outpatients should receive oral clindamycin, TMP-SMX, or a tetracycline (doxycycline/minocycline), while hospitalized patients require IV vancomycin as first-line therapy.
Severity Assessment and Treatment Algorithm
The key decision point is whether this is an outpatient versus hospitalized/complicated infection 1:
Outpatient Management (Purulent Cellulitis/Bullous Lesions)
For patients who can be managed as outpatients with purulent/bullous skin infections:
First-line oral options 1:
- Clindamycin (A-I evidence rating) - strongest evidence
- TMP-SMX (A-II evidence rating)
- Tetracycline - doxycycline or minocycline (A-II evidence rating)
- Linezolid (A-II evidence rating) - reserve for resistant cases
Duration: 5-10 days, individualized based on clinical response 1
Important consideration: If you need to cover both MRSA and β-hemolytic streptococci (which can also cause bullous lesions), use either clindamycin alone OR combine TMP-SMX/tetracycline with a β-lactam like amoxicillin 1
Hospitalized/Complicated Infection Management
For patients requiring hospitalization (severe disease, systemic symptoms, extensive involvement, immunocompromised, extremes of age):
First-line IV therapy 1:
- IV Vancomycin (A-I evidence rating) - gold standard
- Alternatives: Linezolid 600 mg IV/PO twice daily (A-I), Daptomycin 4 mg/kg IV daily (A-I), Telavancin 10 mg/kg IV daily (A-I)
- Clindamycin 600 mg IV/PO three times daily (A-III) - weaker evidence
Duration: 7-14 days based on clinical response 1
Critical Management Steps
1. Culture and Drainage
- Always obtain cultures from bullous lesions before starting antibiotics 1
- Drain any drainable fluid collections - this is essential for treatment success 1
2. Antibiotic Selection Nuances
Clindamycin considerations: While it has the strongest evidence rating (A-I) for outpatient MRSA 1, only use if local clindamycin resistance rates are <10% 1. Check your local antibiogram.
TMP-SMX limitations: Does NOT cover β-hemolytic streptococci 1. If bullous impetigo from Streptococcus is in your differential, add a β-lactam or use clindamycin alone.
Minocycline vs Doxycycline: Some evidence suggests minocycline may be more reliably effective than doxycycline for CA-MRSA 2, though both are guideline-recommended.
3. Pediatric Modifications
For children 1:
- Avoid tetracyclines in children <8 years old (A-II)
- Hospitalized children: Vancomycin is recommended (A-II)
- Stable children without bacteremia: Clindamycin 10-13 mg/kg/dose IV every 6-8 hours if local resistance <10%
- Linezolid dosing: 10 mg/kg every 8 hours for <12 years; 600 mg twice daily for ≥12 years
For bullous impetigo specifically in infants, topical fusidic acid or mupirocin may be considered for localized disease, with flucloxacillin for systemic therapy 3 - though this assumes methicillin-sensitive organisms.
Common Pitfalls to Avoid
Don't use rifampin as monotherapy or adjunctive therapy for skin infections - no proven benefit and promotes resistance 1
Don't assume in-vitro susceptibility equals clinical effectiveness with MRSA 4, 2 - stick to agents with proven in-vivo efficacy
Don't forget source control - antibiotics alone without drainage of purulent collections will fail 1
Don't overlook systemic toxicity indicators requiring hospitalization: multiple sites, rapid progression, fever, hypotension, comorbidities, immunosuppression 1
Evidence Quality Note
These recommendations are based primarily on the 2011 IDSA MRSA guidelines 1 and 2014 IDSA skin/soft tissue infection guidelines 5, which represent the highest quality guideline evidence available. The 2011 MRSA guidelines provide the most comprehensive, evidence-graded recommendations specifically for this clinical scenario.